Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: A randomized double blind placebo controlled trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of fatty liver & elevated liver enzymes.

This study aimed to investigate the impact of vitamin D supplementation in treatment of patients with NAFLD.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Biomarkers, Dietary Supplements, Non-alcoholic Fatty Liver Disease, Prognosis, Vitamin D and Vitamins.

The authors tagged it with the keywords Calcitriol, Clinical trial and Non-alcoholic steatohepatitis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with fatty liver & elevated liver enzymes.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Diabetes & metabolic syndrome), a journal based in Netherlands.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Fatty liver & elevated liver enzymes research.